about
Dissection of the internal carotid artery mimicking episodic cluster headacheThe Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment OptionsTwo decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment.Awareness of headache and of National Headache Society activities among primary care physicians - a qualitative studyRecurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection--a case reportInterferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon βRestless legs syndrome in multiple sclerosis.Posterior tibial nerve stimulation in the management of lower urinary tract symptoms in patients with multiple sclerosis.Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis.Hyperconnectivity of the dorsolateral prefrontal cortex following mental effort in multiple sclerosis patients with cognitive fatigue.Clinical phenotype and outcome of hepatitis E virus-associated neuralgic amyotrophy.Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study.Life-threatening asthma attack during prolonged fingolimod treatment: case report.Maintenance percutaneous posterior nerve stimulation for refractory lower urinary tract symptoms in patients with multiple sclerosis: an open label, multicenter, prospective study.Recurrent myelitis associated with herpes simplex virus type 2.Tumefactive demyelinating lesions during etanercept treatment requiring decompressive hemicraniectomy.Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation.Video-polysomnographic aspects of painful legs and moving toes syndrome.Urinary incontinence in multiple sclerosis: prevalence, severity and impact on patients' quality of life.Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis.Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction.Natalizumab in spinal multiple sclerosis in a daily clinical setting.Forceps minor damage and co-occurrence of depression and fatigue in multiple sclerosis.Intradiploic encephalocele of the primary motor cortex in an adult patient: electrophysiological implications during surgery.Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland.Chronic inflammatory lumbosacral polyradiculopathy: a regional variant of CIDPHydrocephalus during natalizumab treatmentDiffusion-weighted imaging in acute demyelinating myelopathyOcular toxoplasmosis during natalizumab treatmentOver 10-year follow-up of limbic encephalitis associated with anti-LGI1 antibodiesEnhancing clinical decisions about care through a pre-consultation sheet that captures patients' views on their health conditions and treatments: A qualitative study in the field of chronic painMotor and sensory responses after percutaneous tibial nerve stimulation in multiple sclerosis patients with lower urinary tract symptoms treated in daily practiceFumaric acid esters in psoriasis and multiple sclerosisMR neurography of a vagal neuropathySevere articular and musculoskeletal pain: An unexpected side effect of dimethyl-fumarate therapy for multiple sclerosisProdromal symptoms of multiple sclerosis in primary careSerum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosisAtypical Post-Injection Reactions with Delayed Onset Following Glatiramer Acetate 40 mg: Need for Titration?The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most?
P50
Q28219833-FFE0CE79-E065-4E26-B010-D0ABF2C8A560Q28601505-65CCAA70-BC49-43DA-9842-0FED08965BC9Q34090086-CEED8EEF-37A4-4E29-85D3-0AD0CF181611Q34636900-8AA35B55-7887-4120-A90D-17B1657E6BFEQ34674636-A6A5834E-B2DD-40A6-984C-34F19EA7C84FQ34893972-6EFA9ADC-CDCB-444C-A2D4-2E811BFFCE97Q35103997-D0EDD1E2-1034-4669-8987-5120B21A3295Q38067789-8C7E746E-43F7-4267-AEAC-ADF653A3AAC6Q38561380-724E40B5-CB1D-4E8E-B440-D1307981A4C0Q38954336-73F11699-51C9-40C7-AFD2-CE061A6F3404Q40022493-E8D1E2E9-C22F-46BD-8EBC-EA280AB1DC48Q40097605-6390A95B-579C-43E4-BC89-F534A5D6CA6EQ41611259-38923AD1-3DCD-412F-9932-09572146D0A1Q42069511-134AF439-EC14-4D83-AD6E-9CE615C86A0AQ42620559-C8C42BAE-4C1F-4517-AC3C-698097E66E13Q43807752-0808DE7C-29F3-4E34-9A7C-4CF35448E274Q44540131-B0C0047F-7678-4D6E-9242-B06CBA72117DQ47569235-9EEF0BD5-C730-421E-924D-80E3FF544504Q47737311-D818F54B-03EF-4516-863B-C36EEEA7393BQ47763770-650D3943-FA39-4160-B357-852380843F8BQ47975209-95CDF213-84C7-4CF4-8265-8EBE2EF753F2Q48058748-E9FAFD3E-6757-4AD3-AAC1-668917DB0DF9Q48247814-255AEBA1-7CCC-498F-807D-0A1BD979C0DBQ48311935-77B93C3D-AD7E-417D-9746-C55C9A68FE48Q50651152-1E045810-2971-49CB-B10F-768EB382ED2EQ54977502-BBBB6420-3E3A-4FE8-AAD7-E1B8462B9F91Q82068844-3F19D2BF-CCD6-4DAB-87D8-D78A9130295DQ84192373-785748C1-945B-4948-A63B-B0E2D1BCC541Q84534642-B967CF97-7455-4A59-BF87-9BEFC2497938Q84582881-DFB4C5D1-8139-43DF-9CE3-3C9ED0276CF6Q86277856-4C57809C-527E-4F02-8220-0F7779A1A260Q86917653-9CFEBB89-28DF-4AF0-B77F-7995313C9FACQ87031517-5E27D2A8-68DC-470D-994D-71B1D489E146Q87778504-AC7E7EF6-01CB-4017-86DF-AA218C7A345FQ87871152-3CAC35FD-20E7-4460-A462-D496CE6BA5A4Q88379867-BEF98585-2A66-46B8-8A88-C9FF85989834Q88611366-256687FD-A036-4FE2-9D39-136E41032E11Q88960884-CA35201E-90FE-47C6-A57A-5C3CA9D76B1DQ89288955-447D96E1-20ED-4EE0-A07A-2AED1878D0D4Q90614254-348E4445-A7CB-4FCE-8FBB-3634A75DC124
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
C Gobbi
@ast
C Gobbi
@en
C Gobbi
@es
C Gobbi
@nl
C Gobbi
@sl
type
label
C Gobbi
@ast
C Gobbi
@en
C Gobbi
@es
C Gobbi
@nl
C Gobbi
@sl
prefLabel
C Gobbi
@ast
C Gobbi
@en
C Gobbi
@es
C Gobbi
@nl
C Gobbi
@sl
P106
P1153
6701664879
P31
P496
0000-0002-7554-0664